Market Cap 49.44M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 435,400
Avg Vol 120,512
Day's Range N/A - N/A
Shares Out 89.70M
Stochastic %K 30%
Beta 2.18
Analysts Strong Sell
Price Target $5.88

Latest News on CNTX

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Jul 10, 2024, 7:30 AM EDT - 9 months ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95